Evaluation of efficacy, safety, @entity158 perception and health-related quality of life of percutaneous XXXX injection as first-line treatment in symptomatic @entity8426 .

@entity1 @entity8426 @entity158 @entity285 @entity1068
BACKGROUND: To evaluate the efficacy, safety, @entity158 perception and health-related quality of life (QoL) of percutaneous @entity1068 injection treatment (PEIT) as an alternative to thyroid surgery in symptomatic @entity8426 . METHODS: Thirty consecutive @entity1 (46        10  years; 82  % @entity1 ) with symptomatic benign @entity8426 relapsed after drainage were included. In all cases, cytology prior to treatment, maximum cyst diameter and volume were determined. PEIT was conducted using the established procedure, and the volume of fluid removed and @entity158 perceived by the @entity1 were assessed. In each procedure, the volume of @entity285 instilled was   <2  ml. After follow-up, final cyst diameter and volume were determined and the persistence of symptoms and QoL were assessed by a questionnaire (SF-36). RESULTS: Mean symptom duration was 10        20  months. A single session of PEIT was required to complete the procedure in 45  % of @entity1 , two in 31  % and three in 13  %. Mean initial maximum cyst diameter was 3.5        1.0  cm and mean extracted liquid volume 61        36  ml. During PEIT, 39  % of @entity1 experienced virtually no @entity158 , 43  % mild @entity158 and 17  % moderate @entity158 . No complications of PEIT were observed. After 12.1        1.4  months of follow-up, cysts were reduced more than 70  % in volume in 86.3  % of @entity1 , more than 80  % in 61.9  % and more than 90  % in 42  %. On the health-related QoL SF-36 questionnaire, @entity1 scores 6  months post-PEIT did not differ significantly from those of the healthy Spanish population. With respect to cosmetic complaints or local symptoms of compression, PEIT-treated @entity1 presented an initial score of 22        8 and 13        5 after treatment (p   <   0.05). CONCLUSIONS: In our experience, percutaneous @entity1068 injection has prove to be an effective, safe and well-tolerated first-line treatment of symptomatic @entity8426 .
